Treatment Differences Between Drug-Sensitive and Drug-Resistant TB
For drug-sensitive TB, use a 4-month all-oral regimen (2HRZ(E)/2HR) in eligible patients, while drug-resistant TB requires novel shorter regimens containing bedaquiline, pretomanid, and linezolid (BPaL or BPaLM) for 6 months, fundamentally transforming TB treatment from the traditional 6-18+ month approaches. 1
Drug-Sensitive TB Treatment
The 2025 ATS/CDC/ERS/IDSA guidelines represent a paradigm shift from the historical 6-month standard:
Adults with Pulmonary TB
- 4-month regimen: 2 months of isoniazid (H), rifampin (R), pyrazinamide (Z), and ethambutol (E), followed by 2 months of HR
- This replaces the older 2HRZE/4HR (6-month) regimen
- Achieves cure rates above 95% 2
- All-oral, well-tolerated 1
Children (3 months to 16 years)
- 4-month regimen (2HRZ(E)/2HR) for nonsevere TB without MDR/RR-TB suspicion
- Strong recommendation with moderate certainty of evidence 1
- Significantly shorter than the previous 6-month standard
Drug-Resistant TB Treatment
The treatment approach differs dramatically based on resistance pattern:
Rifampin-Resistant, Fluoroquinolone-Susceptible TB
BPaLM regimen for 6 months (bedaquiline, pretomanid, linezolid, moxifloxacin):
- For adolescents ≥14 years and adults
- Replaces 15-month or longer regimens
- Strong recommendation despite very low certainty of evidence 1
- Achieves 93% cure rate—the highest among all DR-TB regimens 3
Rifampin-Resistant with Fluoroquinolone Resistance/Intolerance
BPaL regimen for 6 months (bedaquiline, pretomanid, linezolid without moxifloxacin):
- For patients with no previous bedaquiline/linezolid exposure or <1 month exposure
- Strong recommendation, very low certainty of evidence 1
Extensively Drug-Resistant TB (XDR-TB)
- Individualized combination therapy with at least 4 effective drugs
- Treatment duration typically 18 months 4
- Must include linezolid and clofazimine as key second-line agents when possible 5
- Requires specialized center management 4
Key Operational Differences
Duration
- Drug-sensitive: 4 months (down from 6)
- MDR/RR-TB: 6 months (down from 15-24 months)
- XDR-TB: 18 months individualized 4
Drug Classes
- Drug-sensitive: First-line agents (HRZE) that are well-tolerated
- Drug-resistant: Novel agents (bedaquiline, pretomanid, linezolid) with different toxicity profiles
Monitoring Requirements
Drug-resistant TB demands more intensive monitoring:
- Comprehensive phenotypic and molecular drug susceptibility testing (DST) via whole-genome sequencing 6
- Higher adverse event rates: 65% overall AEs, 17% serious AEs 3
- Most common toxicities with BPaL/BPaLM: peripheral neuropathy (9.8%), bone marrow suppression (5.2%), hematological abnormalities (5.1%) 3
Treatment Success Rates
- Drug-sensitive TB: 95% WHO-defined success 6
- MDR/RR-TB with BPaL/BPaLM: 87-93% success 6, 3
- Traditional long-course MDR-TB regimens: 62% cure rate 3
Critical Caveats
Severe disease considerations: In cases of extensive pulmonary disease or immunosuppression with drug-resistant TB, extend the 6-month regimens to 9 months or use individualized 18-month regimens 4. This is a crucial clinical decision point that prevents treatment failure.
Geographic variation matters: Europe achieves 84% cure rates for DR-TB versus lower rates in other regions, reflecting healthcare infrastructure differences 3. This underscores the importance of programmatic support beyond just drug selection.
Drug susceptibility testing is non-negotiable: High concordance between phenotypic DST and whole-genome sequencing (WGS) supports using molecular DST to rapidly guide individualized treatment 6. Waiting for culture-based DST delays appropriate therapy and worsens outcomes.
Specialist involvement: All drug-resistant TB should be managed by or in consultation with specialized centers due to complexity of regimen selection, toxicity management, and need for secure drug supply 4, 7.